Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors

Exelixis, Inc. (Nasdaq:EXEL) announced on 6/1/2018 an amendment to the protocol for COSMIC-021, the phase 1b trial of cabozantinib (Cabometyx) in combination with atezolizumab (Tecentriq) in patients with locally advanced or metastatic solid tumors to add 10 new expansion cohorts to the trial. The primary objective in the expansion stage of this trial remains to determine the objective response rate in each cohort.